• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

抗 HIV-TB 共感染病原体的多靶标分子的研究进展综述。

A Review of the Development of Multitarget Molecules against HIV-TB Coinfection Pathogens.

机构信息

Laboratorio de Sintese de Farmacos (LASFAR), Fundacao Oswaldo Cruz, Instituto de Tecnologia em Farmacos (Farmanguinhos), Fiocruz, Rua Sizenando Nabuco, 100 Manguinhos, Rio de Janeiro 21041-000, Brazil.

Programa de Pos-Graduação em Farmacologia e Química Medicinal, Instituto de Ciências Biomédicas (ICB), Universidade Federal do Rio de Janeiro (UFRJ), Av. Carlos Chagas Filho, Rio de Janeiro 21941-902, Brazil.

出版信息

Molecules. 2023 Apr 10;28(8):3342. doi: 10.3390/molecules28083342.

DOI:10.3390/molecules28083342
PMID:37110574
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10143421/
Abstract

The human immunodeficiency virus (HIV) produces the pathologic basis of acquired immunodeficiency syndrome (AIDS). An increase in the viral load in the body leads to a decline in the number of T lymphocytes, compromising the patient's immune system. Some opportunistic diseases may result, such as tuberculosis (TB), which is the most common in seropositive patients. Long-term treatment is required for HIV-TB coinfection, and cocktails of drugs for both diseases are used concomitantly. The most challenging aspects of treatment are the occurrence of drug interactions, overlapping toxicity, no adherence to treatment and cases of resistance. Recent approaches have involved using molecules that can act synergistically on two or more distinct targets. The development of multitarget molecules could overcome the disadvantages of the therapies used to treat HIV-TB coinfection. This report is the first review on using molecules with activities against HIV and (MTB) for molecular hybridization and multitarget strategies. Here, we discuss the importance and development of multiple targets as a means of improving adherence to therapy in cases of the coexistence of these pathologies. In this context, several studies on the development of structural entities to treat HIV-TB simultaneously are discussed.

摘要

人类免疫缺陷病毒 (HIV) 产生获得性免疫缺陷综合征 (AIDS) 的病理基础。体内病毒载量的增加导致 T 淋巴细胞数量减少，从而损害患者的免疫系统。可能会发生一些机会性疾病，如结核病 (TB)，这在血清阳性患者中最为常见。HIV-TB 合并感染需要长期治疗，并且同时使用两种疾病的药物鸡尾酒。治疗中最具挑战性的方面是药物相互作用的发生、重叠毒性、不遵医嘱和耐药性病例。最近的方法涉及使用可以协同作用于两个或多个不同靶点的分子。开发多靶分子可以克服用于治疗 HIV-TB 合并感染的疗法的缺点。本报告是第一篇关于使用针对 HIV 和结核分枝杆菌 (MTB) 的活性分子进行分子杂交和多靶点策略的综述。在这里，我们讨论了作为提高这些病理共存时治疗依从性的一种手段的多个靶点的重要性和发展。在这方面，讨论了针对同时治疗 HIV-TB 的结构实体的开发的几项研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93c7/10143421/95840dcf3b28/molecules-28-03342-g023.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93c7/10143421/121a4a53f8e1/molecules-28-03342-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93c7/10143421/cf3fff5a7255/molecules-28-03342-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93c7/10143421/48f65dd38126/molecules-28-03342-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93c7/10143421/a0a38c04cbd8/molecules-28-03342-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93c7/10143421/3ba073424526/molecules-28-03342-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93c7/10143421/b99b3603fb4b/molecules-28-03342-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93c7/10143421/e1ddb1f98fa3/molecules-28-03342-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93c7/10143421/c9a6d8f7cf13/molecules-28-03342-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93c7/10143421/ce829276d10a/molecules-28-03342-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93c7/10143421/5b1977377da7/molecules-28-03342-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93c7/10143421/ecf0bda7c5a3/molecules-28-03342-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93c7/10143421/3b82fa4d0612/molecules-28-03342-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93c7/10143421/f11f84374e7f/molecules-28-03342-g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93c7/10143421/2f50e27ddb60/molecules-28-03342-g014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93c7/10143421/182b0c95ebe1/molecules-28-03342-g015.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93c7/10143421/cd3661e13888/molecules-28-03342-g016.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93c7/10143421/e637b95666eb/molecules-28-03342-g017.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93c7/10143421/81b7ae290837/molecules-28-03342-g018.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93c7/10143421/8da759153237/molecules-28-03342-g019.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93c7/10143421/9fa0c7916e9b/molecules-28-03342-g020.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93c7/10143421/6f2d8e2a66b4/molecules-28-03342-g021.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93c7/10143421/848176470cca/molecules-28-03342-g022.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93c7/10143421/95840dcf3b28/molecules-28-03342-g023.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93c7/10143421/121a4a53f8e1/molecules-28-03342-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93c7/10143421/cf3fff5a7255/molecules-28-03342-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93c7/10143421/48f65dd38126/molecules-28-03342-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93c7/10143421/a0a38c04cbd8/molecules-28-03342-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93c7/10143421/3ba073424526/molecules-28-03342-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93c7/10143421/b99b3603fb4b/molecules-28-03342-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93c7/10143421/e1ddb1f98fa3/molecules-28-03342-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93c7/10143421/c9a6d8f7cf13/molecules-28-03342-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93c7/10143421/ce829276d10a/molecules-28-03342-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93c7/10143421/5b1977377da7/molecules-28-03342-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93c7/10143421/ecf0bda7c5a3/molecules-28-03342-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93c7/10143421/3b82fa4d0612/molecules-28-03342-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93c7/10143421/f11f84374e7f/molecules-28-03342-g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93c7/10143421/2f50e27ddb60/molecules-28-03342-g014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93c7/10143421/182b0c95ebe1/molecules-28-03342-g015.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93c7/10143421/cd3661e13888/molecules-28-03342-g016.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93c7/10143421/e637b95666eb/molecules-28-03342-g017.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93c7/10143421/81b7ae290837/molecules-28-03342-g018.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93c7/10143421/8da759153237/molecules-28-03342-g019.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93c7/10143421/9fa0c7916e9b/molecules-28-03342-g020.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93c7/10143421/6f2d8e2a66b4/molecules-28-03342-g021.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93c7/10143421/848176470cca/molecules-28-03342-g022.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93c7/10143421/95840dcf3b28/molecules-28-03342-g023.jpg

相似文献

1
A Review of the Development of Multitarget Molecules against HIV-TB Coinfection Pathogens.抗 HIV-TB 共感染病原体的多靶标分子的研究进展综述。
Molecules. 2023 Apr 10;28(8):3342. doi: 10.3390/molecules28083342.
2
New azaaurone derivatives as potential multitarget agents in HIV-TB coinfection.新型氮茚酮衍生物有望成为 HIV-TB 合并感染的多靶点药物。
Arch Pharm (Weinheim). 2024 Feb;357(2):e2300560. doi: 10.1002/ardp.202300560. Epub 2023 Nov 30.
3
Tuberculosis and HIV Coinfection.结核病与艾滋病病毒合并感染
Cold Spring Harb Perspect Med. 2015 Feb 26;5(7):a017871. doi: 10.1101/cshperspect.a017871.
4
Tuberculosis: burning issues: multidrug resistance and HIV-coinfection.结核病：热点问题：耐多药和 HIV 合并感染。
Crit Rev Microbiol. 2012 Nov;38(4):267-75. doi: 10.3109/1040841X.2012.664539. Epub 2012 Mar 16.
5
[Tuberculosis and HIV co-infection: a therapeutic challenge].[结核病与艾滋病毒合并感染：一项治疗挑战]
Rev Med Suisse. 2011 Nov 23;7(318):2295-6, 2298-300.
6
Characterization of 2-hydroxy-1-naphthaldehyde isonicotinoyl hydrazone as a novel inhibitor of methionine aminopeptidases from Mycobacterium tuberculosis.2-羟基-1-萘甲醛异烟酰腙作为结核分枝杆菌甲硫氨酸氨基肽酶新型抑制剂的表征
Tuberculosis (Edinb). 2016 Dec;101S:S73-S77. doi: 10.1016/j.tube.2016.09.025. Epub 2016 Sep 28.
7
Association between antiretroviral therapy and antitubercular drug resistance in TB treatment outcome among Kazakh TB/HIV co-infected patients.哈萨克斯坦结核/艾滋病毒合并感染患者中抗逆转录病毒治疗与抗结核药物耐药性对结核治疗结局的关系。
J Glob Antimicrob Resist. 2018 Sep;14:104-108. doi: 10.1016/j.jgar.2018.02.015. Epub 2018 Feb 26.
8
A Markov model for the effects of virological failure on HIV/AIDS progression in tuberculosis co-infected patients receiving antiretroviral therapy in a rural clinic in northern South Africa.南非北部农村诊所接受抗逆转录病毒疗法的结核合并 HIV 感染者中病毒学失败对 HIV/AIDS 进展影响的马尔可夫模型。
S Afr Med J. 2020 Mar 30;110(4):313-319. doi: 10.7196/SAMJ.2020.v110i4.13934.
9
Risk assessment of hepatotoxicity among tuberculosis and human immunodeficiency virus/AIDS-coinfected patients under tuberculosis treatment.结核病治疗中合并感染人类免疫缺陷病毒/艾滋病的患者肝毒性的风险评估
Int J Mycobacteriol. 2016 Dec;5(4):482-488. doi: 10.1016/j.ijmyco.2016.05.003. Epub 2016 Jun 6.
10
Immune reconstitution inflammatory syndrome presenting as chylothorax in a patient with HIV and Mycobacterium tuberculosis coinfection: a case report.HIV 与结核分枝杆菌合并感染患者发生免疫重建炎症综合征并乳糜胸：病例报告
BMC Infect Dis. 2010 Nov 8;10:321. doi: 10.1186/1471-2334-10-321.

引用本文的文献

1
A novel web-based risk calculator for predicting surgical site infection in HIV-positive facture patients: a multicenter cohort study in China.一种新型基于网络的风险计算器，用于预测 HIV 阳性骨折患者的手术部位感染：中国多中心队列研究。
Front Cell Infect Microbiol. 2024 Jun 26;14:1408388. doi: 10.3389/fcimb.2024.1408388. eCollection 2024.
2
Optimizing antigen selection for the development of tuberculosis vaccines.优化用于结核病疫苗研发的抗原选择。
Cell Insight. 2024 Mar 16;3(3):100163. doi: 10.1016/j.cellin.2024.100163. eCollection 2024 Jun.
3
CD4 T cell count in HIV/TB co-infection and co-occurrence with HL: Case report and literature review.

本文引用的文献

1
Overview of Side-Effects of Antibacterial Fluoroquinolones: New Drugs versus Old Drugs, a Step Forward in the Safety Profile?氟喹诺酮类抗菌药物的副作用概述：新药与旧药对比，安全性方面是否有所进步？
Pharmaceutics. 2023 Mar 1;15(3):804. doi: 10.3390/pharmaceutics15030804.
2
The Use of Zidovudine Pharmacophore in Multi-Target-Directed Ligands for AIDS Therapy.齐多夫定药效团在抗艾滋病多靶标导向药物中的应用。
Molecules. 2022 Dec 3;27(23):8502. doi: 10.3390/molecules27238502.
3
Role of macrophages in HIV pathogenesis and cure: NIH perspectives.
HIV/TB合并感染及与HL同时发生时的CD4 T细胞计数：病例报告与文献综述
Open Life Sci. 2023 Sep 20;18(1):20220744. doi: 10.1515/biol-2022-0744. eCollection 2023.
巨噬细胞在 HIV 发病机制和治疗中的作用：NIH 的观点。
J Leukoc Biol. 2022 Nov;112(5):1233-1243. doi: 10.1002/JLB.4MR0722-619R. Epub 2022 Sep 8.
4
Animal models for studies of HIV-1 brain reservoirs.用于 HIV-1 脑库研究的动物模型。
J Leukoc Biol. 2022 Nov;112(5):1285-1295. doi: 10.1002/JLB.5VMR0322-161R. Epub 2022 Aug 31.
5
Past HIV-1 Medications and the Current Status of Combined Antiretroviral Therapy Options for HIV-1 Patients.过去用于治疗HIV-1的药物及HIV-1患者联合抗逆转录病毒治疗方案的现状
Pharmaceutics. 2021 Oct 27;13(11):1798. doi: 10.3390/pharmaceutics13111798.
6
Pyrroles as Privileged Scaffolds in the Search for New Potential HIV Inhibitors.吡咯作为寻找新型潜在HIV抑制剂的优势骨架。
Pharmaceuticals (Basel). 2021 Sep 2;14(9):893. doi: 10.3390/ph14090893.
7
Integrase inhibitors versus efavirenz combination antiretroviral therapies for TB/HIV coinfection: a meta-analysis of randomized controlled trials.整合酶抑制剂与依非韦伦联合抗逆转录病毒疗法治疗结核/艾滋病毒合并感染：随机对照试验的荟萃分析。
AIDS Res Ther. 2021 May 1;18(1):25. doi: 10.1186/s12981-021-00348-w.
8
Block-And-Lock: New Horizons for a Cure for HIV-1.阻断与锁定：治愈HIV-1的新视野
Viruses. 2020 Dec 15;12(12):1443. doi: 10.3390/v12121443.
9
Haemopoietic cell transplantation in patients living with HIV.HIV 感染者的造血细胞移植。
Lancet HIV. 2020 Sep;7(9):e652-e660. doi: 10.1016/S2352-3018(20)30117-X. Epub 2020 Aug 10.
10
From combinations to multitarget-directed ligands: A continuum in Alzheimer's disease polypharmacology.从组合到多靶点导向配体：阿尔茨海默病多药理学的连续体
Med Res Rev. 2021 Sep;41(5):2606-2633. doi: 10.1002/med.21699. Epub 2020 Jun 19.